Results 21 to 30 of about 14,385 (213)

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors [PDF]

Haematologica, 2018
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least
Rajeswaran Mani, Swagata Goswami, Bhavani Gopalakrishnan, Rahul Ramaswamy, Ronni Wasmuth, Minh Tran, Xiaokui Mo, Amber Gordon, Donna Bucci, David M. Lucas, Alice Mims, Christopher Brooks, Adrienne Dorrance, Alison Walker, William Blum, John C. Byrd, Gerard Lozanski, Sumithira Vasu, Natarajan Muthusamy   +18 more
doaj   +2 more sources

Blastic plasmacytoid dendritic cell neoplasm in a young female: Rare and challenging

Indian Journal of Medical and Paediatric Oncology, 2020
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematopoietic malignancy with an aggressive behavior, seen commonly in the elderly age group and usually involves the skin.
Ketan Modak, Jeevan Kumar Garg, Deepak Kumar Mishra, Vivek S Radhakrishnan   +3 more
doaj   +1 more source

Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment

OncoImmunology, 2021
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse.
Hélène Bonnevaux, Stephane Guerif, Jana Albrecht, Erwan Jouannot, Thibaud De Gallier, Christian Beil, Christian Lange, Wulf Dirk Leuschner, Marion Schneider, Cendrine Lemoine, Anne Caron, Céline Amara, Cédric Barrière, Justine Siavellis, Valérie Bardet, Ernesto Luna, Pankaj Agrawal, Donald R. Drake, Ercole Rao, Peter Wonerow, Chantal Carrez, Véronique Blanc, Karl Hsu, Dmitri Wiederschain, Paula G. Fraenkel, Angéla Virone-Oddos   +25 more
doaj   +1 more source

The CD123 antibody–drug conjugate pivekimab sunirine exerts profound activity in preclinical models of pediatric acute lymphoblastic leukemia [PDF]

HemaSphere
Antibody–drug conjugates (ADCs) combining monoclonal antibodies with cytotoxic payloads are a rapidly emerging class of immune‐based therapeutics with the potential to improve the treatment of cancer, including children with relapse/refractory acute ...
Ben Watts, Christopher M. Smith, Kathryn Evans, Andrew J. Gifford, Sara M. A. Mohamed, Stephen W. Erickson, Eric J. Earley, Steven Neuhauser, Timothy M. Stearns, Vivek M. Philip, Jeffrey H. Chuang, Patrick A. Zweidler‐McKay, Sribalaji Lakshmikanthan, Emily L. Jocoy, Carol J. Bult, Beverly A. Teicher, Malcolm A. Smith, Richard B. Lock   +17 more
doaj   +2 more sources

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia

Haematologica, 2009
We evaluated CD123 expression in 95 pediatric and 24 adult ALL patients and compared the results with the CD123 expression in normal B-cell precursors.
Miroslav Djokic, Elisabet Björklund, Elisabeth Blennow, Joanna Mazur, Stefan Söderhäll, Anna Porwit   +5 more
doaj   +1 more source

Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy [PDF]

, 2023
Targeted eradication of transformed or otherwise dysregulated cells using monoclonal antibodies (mAb), antibody-drug conjugates (ADC), T cell engagers (TCE), or chimeric antigen receptor (CAR) cells is very effective for hematologic diseases.
Schwede, Torsten, Dell'Aglio, Alessandro, Sinopoli, Alessandro, Gallagher, Danielle N., Do Sacramento, Valentin, Corn, Jacob; id_orcid, Schröder, Markus S., Bordoli, Lorenza, Urlinger, Stefanie, Porteus, Matthew, Zuin, Jessica, Xu, Liwen, Wiederkehr, Amélie, Garcia-Prat, Laura, Simonetta, Federico, Cathomen, Toni, Devaux, Anna, Camus, Anna, Lepore, Rosalba, Rhiel, Manuel, Haydn, Anna, Landmann, Emmanuelle, Seyres, Denis, Andrieux, Geoffroy, Engdahl, Corinne, Capoferri, Giuseppina, Marone, Romina, Cornu, Tatjana I., Corn, Jacob E., Divsalar, Christopher, Burgold, Thomas, Jeker, Lukas T., Larrue, Clément, Rositzka, Julia, Schröder, Markus Sebastian; id_orcid, Tamburini, Jérôme   +35 more
core   +2 more sources

Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123

, 2023
International audienceCD123, the alpha chain of the IL-3 receptor, is an attractive target for acute myeloid leukemia (AML) treatment. However, cytotoxic antibodies or T cell engagers targeting CD123 had insufficient efficacy or safety in clinical trials.
Rossi, Benjamin, Grondin, Gwendoline, Gauthier, Laurent, Bauchet, Anne-Laure, Eric Vivier, Audrey Blanchard-Alvarez, Alexandra Basset, Anne-Laure Bauchet, Agnel, Magali, Nicolazzi, Céline, Laurent Gauthier, Gourdin, Nicolas, Jacqueline Courta, Basset, Alexandra, Beninga, Jochen, Morel, Ariane, Morel, Yannis, Chiron, Marielle, Benjamin Rossi, Magali Agnel, Hélène Bonnevaux, Courta, Jacqueline, Gwendoline Grondin, Bonnevaux, Hélène, Céline Nicolazzi, Marielle Chiron, Blanchard-Alvarez, Audrey, Vivier, Eric, Céline Amara, Ariane Morel, Franceline Guillot, Guillot, Franceline, Nicolas Gourdin, Amara, Céline, Angela Virone-Oddos, Yannis Morel, Virone-Oddos, Angela, Jochen Beninga   +37 more
core   +1 more source

Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML

OncoImmunology, 2021
Chimeric antigen receptor T cells (CAR-T) targeting CD19 have achieved significant success in patients with B cell malignancies. To date, implementation of CAR-T in other indications remains challenging due to the lack of truly tumor-specific antigens as
Jan-Erik Meyer, Simon Loff, Josephine Dietrich, Johannes Spehr, Gabriel Jurado Jiménez, Malte von Bonin, Gerhard Ehninger, Marc Cartellieri, Armin Ehninger   +8 more
doaj   +1 more source

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models

Frontiers in Immunology, 2022
Immunotherapy with T-cells expressing bispecific T-cell engagers (ENG T-cells) is a promising approach to improve the outcomes for patients with recurrent/refractory acute myeloid leukemia (AML).
Hong Mu-Mosley, Lauren Ostermann, Muharrem Muftuoglu, Abishek Vaidya, Challice L. Bonifant, Mireya Paulina Velasquez, Stephen Gottschalk, Michael Andreeff   +7 more
doaj   +1 more source

High Expression of Interleukin-3 Receptor Alpha Chain (CD123) Predicts Favorable Outcome in Pediatric B-Cell Acute Lymphoblastic Leukemia Lacking Prognosis-Defining Genomic Aberrations

Frontiers in Oncology, 2021
BackgroundAberrant expression of CD123 (IL-3Rα) was observed in various hematological malignancies including acute lymphoblastic leukemia (ALL), which is the most common malignancy in childhood.
Zhiheng Li, Zhiheng Li, Zhiheng Li, Xinran Chu, Li Gao, Jing Ling, Peifang Xiao, Jun Lu, Yi Wang, Hailong He, Jianqin Li, Yixin Hu, Jie Li, Jian Pan, Sheng Xiao, Shaoyan Hu   +15 more
doaj   +1 more source